Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06178068
Other study ID # B.30.2.ATA.0.01.00/122
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date January 1, 2025

Study information

Verified date December 2023
Source Ataturk University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

COPD is a heterogeneous condition caused by airway (bronchitis/bronchiolitis) or alveolar (emphysema) abnormality, changes with chronic respiratory changes (dyspnea, dyspnoea, phlegm). It is characterized by persistent and frequently progressive airway obstruction. In COPD, which progresses with high mortality, non-pharmacological treatments are applied, as well as pharmacological treatments. They have an essential place in slowing down the progressive course of this treatment. However, despite the treatment administered to COPD patients, outdoor weather conditions, improper use of inhaler treatments, or comorbidities may cause acute exacerbation of COPD. Dry air nebulizer devices use dry air from the central system in hospitals. This system, which converts bronchodilator drugs into nebulizers by creating high currents, works like classical nebulizers without an electrical system and can have a higher flow rate than jet nebulizer devices. This procedure, which can be applied to COPD patients without giving high-flow oxygen, prevents carbon dioxide retention. There is no study in the literature comparing the bronchodilator effectiveness of dry air, classical nebulizer, and jet nebulizer, and the investigators aimed to compare the efficacy of these three treatment modalities in our study.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 39
Est. completion date January 1, 2025
Est. primary completion date April 1, 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Group E COPD patients Exclusion Criteria: - Recent MI - Pulmonary embolism - Cerebral aneurysm - Active hemoptysis - Pneumothorax - Nausea, vomiting - Recent thorax, abdominal, and eye surgery were identified in the patients before the pulmonary function test and were not included in the study. - Mental retardation - Pneumonia with acute exacerbation of COPD - Patients with pulmonary edema due to congestive heart failure - Patients with interstitial lung disease along with COPD

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Comparison of bronchodilator effectiveness of nebulizer therapy devices
The Respirox® RNEB-18 device was used for the bronchodilator treatment given before the randomization of the patients and for the maintenance bronchodilator treatment given in Group 1 patients. After calibrating the device, it was determined that it performed nebulization with a flow of 6 lt/min. In Group 2 patients, a HAVELSAN® EHSIM brand nebulizer produced in our country, compatible with the central system of our hospital, was used as a dry air nebulizer. For classical nebulizer treatment in Group 3 patients, a nebulizer device compatible with our hospital's central oxygen system was used. In Group 2 and 3 patients, the flow system could be adjusted manually. To be consistent with Group 1 patients, bronchodilator treatment was administered at a 6 lt/min flow rate.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ataturk University

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluation of the change in respiratory function test parameters after 5 days of nebulizer treatment applications.randomization on respiratory function tests Measurement of % change in FVC, FEV1, RV, TLC level 5 days
Primary Evaluation of the change in arterial blood gas parameters after 5 days of nebulizer treatment applications.randomization on respiratory function tests Saturation %, measurement of change in partial oxygen and partial carbon dioxide levels in mm_Hg 5 days
See also
  Status Clinical Trial Phase
Terminated NCT05418777 - Treatment of Pneumocystis in COPD (the TOPIC Study) Phase 1/Phase 2
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Completed NCT03286855 - Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD) N/A
Recruiting NCT06021990 - Clopidogrel for the Prevention of Exacerbations in Severe COPD Phase 3
Completed NCT05218525 - Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Recruiting NCT05734365 - COPD-ICU Multicentre Prospective Observational Register
Completed NCT03464695 - Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD N/A
Recruiting NCT04881409 - Nasal High-flow Compared to Non-invasive Ventilation in Treatment of Acute Acidotic Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Completed NCT05182294 - Tolerance and Acute Effects of a New HFNT Nasal Cannula N/A
Completed NCT04821869 - ProAir Digihaler in COPD Disease Management: A Real World Study
Recruiting NCT06274957 - The Effect of Airway and Chest Wall Oscillation on Respiratory Functions in COPD Patients in Acute Exacerbation N/A
Recruiting NCT05783544 - Impact of A. Lumbricoides on Pulmonary Aspergillosis Development N/A
Recruiting NCT06331416 - Multiparametric Home Telemonitoring of Patients With Chronic Obstructive Pulmonary Disease Exacerbation N/A
Not yet recruiting NCT05703919 - Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease Phase 4
Not yet recruiting NCT06419036 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 1
Not yet recruiting NCT06419062 - The Use of Medical Devices to Monitor Chronic Obstructive Pulmonary Disease Patients Study BREATH-TRACHER 2
Recruiting NCT05764993 - Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention Phase 2
Completed NCT06040931 - Airway Inflammation, Small Airways Dysfunction, and Frequency of Exacerbations in COPD N/A
Active, not recruiting NCT04192175 - Identification of Patients Admitted With COPD Exacerbations and Predicting Readmission Risk Using Machine Learning